| HOME >> BIOLOGY >> TECHNOLOGY |
share and therefore these measures do not reflect the full economic
effect of the reduction in value of those intangible assets.
-- Revenue growth rates stated on a constant currency basis, by their
nature, exclude the impact of foreign exchange, which may have a
material impact on GAAP net sales.
-- Other companies may calculate non-GAAP net income, non-GAAP net income
per diluted share, or regional and divisional revenue growth rates that
exclude the impact of foreign exchange differently than Boston
Scientific does, limiting the usefulness of those measures for
comparative purposes.
Compensation for Limitations Associated with Use of Non-GAAP Financial
Measures
Boston Scientific compensates for the limitations on its non-GAAP
financial measures by relying upon its GAAP results to gain a complete
picture of the Company's performance. The non-GAAP numbers focus instead
upon the core business of the Company, which is only a subset, albeit a
critical one, of the Company's performance.
The Company provides detailed reconciliations of each non-GAAP financial
measure to its most directly comparable GAAP measure in the accompanying
schedules, and Boston Scientific encourages investors to review these
reconciliations.
Usefulness of Non-GAAP Financial Measures to Investors
The Company believes that presenting non-GAAP net income, non-GAAP net
income per share, and regional and divisional revenue growth rates that
exclude the impact of foreign exchange in addition to the related GAAP
measures provides investors greater transparency to the information used
by Boston Scientific management for its financial and operational
decision-making and allows investors to see Boston Scientific's results
"through the eyes" of management. The Company further believes that
providing thi
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |